After more than a year of ban on imports, the company forced the company to remove blood oxygen monitoring from some US Apple Watch models, Apple says it will introduce a newly designed version of this feature today. In a post on its newsroom website, the company says this feature will see Ultra 2 users through the Apple Watch Series 9, Series 10, and the Apple Watch and iPhone shared update. Once Apple starts the software, you will need to update your devices in 18.6.1 and watch OS 11.6.1 to access the work feature again. After refreshing, oxygen data in any blood obtained by your Apple Watch will be calculated on your iPhone, resulting in the health app to seeable data in the respiratory section.
Apple said, “The previously purchased Apple Watch units will not have any effect, including the actual blood oxygen feature, nor on the Apple Watch units purchased outside the United States.”
Today’s update indicates another unexpected development in developing Apple’s long, legal dispute with Missimo. In 2021, the medical device maker sued Apple, and alleged that Tech Dev violated its intellectual features regarding Plus oximator blood oxygen monitoring technology. Legally a few years legally, the matter came to the fore when the US International Trade Commission (ITC) upheld the decision earlier, in which it was discovered that Apple had violated Masimo’s patent. After former President Biden selected the decision not to veto the decision, Apple was forced to temporarily stop the Apple Watch Series 9 and Ultra -2 temporarily sales. The company later resumed sales of re -selling after a refreshing. Now Apple says that due to the recent US customs decision, with a minor amendment, it is able to offer re -activation.
